MannKind Corporation
MNKD Healthcare Biotechnology
MannKind Corporation’s revenue for fiscal 2025 (year ended December 2025) was $349.0 million, up 22.2% from fiscal 2024. In the quarter to June 2026, revenue grew 42.9%, EPS fell 2,827.3%, free cash flow fell 399.4% and total debt rose 201.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow MNKD
MannKind Corporation (MNKD) Piotroski F-score
MannKind Corporation's Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, down from 7 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | (3.00) |
| FY2024 | 7 | 0.00 |
| FY2023 | 7 | 4.00 |
| FY2022 | 3 | 0.00 |
| FY2021 | 3 | (1.00) |
| FY2020 | 4 | 1.00 |
| FY2019 | 3 | (3.00) |
| FY2018 | 6 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 0.99% | 6.35% | Pass | 1 |
| Positive operating cash flow | 18.26m | 42.51m | Pass | 1 |
| Rising return on assets | 0.99% | 6.35% | Fail | 0 |
| Cash flow above net income | 12.39m | 14.92m | Pass | 1 |
| Falling long-term leverage | 0.69 | 0.30 | Fail | 0 |
| Rising current ratio | 1.70 | 3.28 | Fail | 0 |
| No new shares issued | 305,639,000 | 274,415,000 | Fail | 0 |
| Rising gross margin | 74.79% | 73.17% | Pass | 1 |
| Rising asset turnover | 0.59 | 0.66 | Fail | 0 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| MGTX MeiraGTx Holdings PLC compare | 5 |
| MNKD MannKind Corporation | 4 |
| IMTX Immatics N.V. compare | 3 |
| JANX Janux Therapeutics, Inc. compare | 2 |
| VOR Vor Biopharma Inc. compare | — |
| REPL Replimune Group, Inc. compare | — |
| SVRA Savara Inc. compare | — |
| NBTX Nanobiotix S.A. - Sponsored ADR compare | — |
| DMRA Galecto, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover